Loading...
•
Mar 31, 2024
Seres Therapeutics Q1 2024 Earnings Report
Seres Therapeutics reported first quarter 2024 financial results and provided business updates.
Key Takeaways
Seres Therapeutics reported VOWST net sales of $10.1 million in Q1 2024, with approximately 1,411 patient enrollment forms received and approximately 1,083 new patient starts. The company's net loss for the quarter was $40.1 million, as compared to a net loss of $71.2 million for the same period in 2023.
VOWST net sales reached $10.1 million in Q1 2024, driven by continued market adoption.
Approximately 1,411 patient enrollment forms were received, with approximately 1,083 new patient starts in Q1 2024.
SER-155 Phase 1b Cohort 2 clinical readout is expected by the end of Q3 2024.
Seres is evaluating options to secure additional capital to advance its pipeline.
Forward Guidance
Seres anticipates having sufficient resources to support operations through obtaining the SER-155 Cohort 2 data and into the fourth quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...